Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

NCT06388122 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06388122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06388122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Recruiting
Start date
April 30, 2024
Completion date
June 15, 2031
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage ii breast cancer ajcc v8, anatomic stage iii breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, her2 negative breast carcinoma, her2-negative breast cancer, hormone receptor positive breast carcinoma, hormone-receptor-positive breast cancer, metastatic breast cancer, metastatic breast carcinoma